Trial Profile

AZD9291 in EGFR exon 20 insertion mutations

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 11 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Osimertinib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms AEX20

Most Recent Events

06 May 2021 Status changed from active, no longer recruiting to completed.
10 Apr 2021 Results (n=12; Feb 2020) assessing efficacy in patients enrolled in stage 1 of this trial presented at the 112th Annual Meeting of the American Association for Cancer Research
28 Sep 2020 Planned End Date changed from 31 May 2021 to 31 Dec 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com